Antibiotic infusion statistics at a glance
Antibiotic infusion statistics sit at the intersection of stewardship, prescribing behavior, and drug-label administration instructions. The numbers below show how outpatient use, hospital stewardship, long-term care, dialysis care, and FDA infusion guidance all connect (CDC antibiotic use report; FDA labels).
Table of contents
- Fast facts
- Outpatient antibiotic infusion and prescribing patterns
- Hospital and long-term care stewardship benchmarks
- Intravenous antibiotic use in hemodialysis
- What FDA labels say about infusion timing and adverse reactions
- How to read these statistics together
Fast facts
Big number: In 2024, the overall outpatient antibiotic prescribing rate in U.S. retail pharmacies was 752 prescriptions per 1,000 patient population (CDC antibiotic use report).
Stewardship benchmark: In 2024, 97% of hospitals met all 7 CDC hospital antibiotic stewardship core elements, while only 16% met all six CDC hospital stewardship priorities (CDC antibiotic use report).
Dialysis signal: Among outpatient hemodialysis patients, almost one in three receives an intravenous antibiotic each year (CDC antibiotic use report).
Labeling reminder: DALVANCE is administered by intravenous infusion over 30 minutes to minimize infusion-related reactions (Dalvance FDA label).
A useful way to read antibiotic infusion statistics is to separate three layers:
- How often antibiotics are prescribed overall.
- How consistently systems meet stewardship standards.
- How individual drugs are labeled and delivered by infusion.
That structure makes the dataset easier to use for operations, patient education, and policy review.
Outpatient antibiotic infusion and prescribing patterns
The outpatient side of the dataset starts with broad prescribing volume rather than infusion alone. In 2024, the overall outpatient antibiotic prescribing rate in U.S. retail pharmacies was 752 prescriptions per 1,000 patient population, and that rate was down 1% from 2023 (CDC antibiotic use report). That is not a small operational detail. It means antibiotic use remained high enough to matter at the population level, even with a modest year-over-year decline.
One practical reading of that figure is that outpatient antibiotic exposure remains common enough that stewardship conversations cannot be limited to hospitals. The CDC report also shows that in 2021, 7% to 9% of outpatient visits in which antibiotics were prescribed were telemedicine visits (CDC antibiotic use report). That share matters because prescribing context can change when the encounter moves away from an in-person exam.
The most striking telemedicine number in the dataset is the sinusitis result: for sinusitis telemedicine visits, about 75% resulted in an antibiotic prescription (CDC antibiotic use report). That is a reminder that site of care can affect prescribing behavior even when the patient population is still outpatient.
Quick outpatient takeaways
- The outpatient prescribing rate stayed high at 752 per 1,000 in 2024 (CDC antibiotic use report).
- The 2024 rate was only 1% below 2023, so the year-over-year change was modest (CDC antibiotic use report).
- Telemedicine accounted for 7% to 9% of outpatient antibiotic-prescribing visits in 2021 (CDC antibiotic use report).
- Sinusitis telemedicine visits had an antibiotic prescription rate of about 75% (CDC antibiotic use report).
The dataset also identifies who is doing much of the prescribing. In 2022, family practice, nurse practitioner, and internal medicine clinicians prescribed 52% of outpatient antibiotic prescriptions among Medicare Part D beneficiaries (CDC antibiotic use report). That concentration suggests that a relatively small set of clinician groups influences a large share of outpatient antibiotic exposure.
Another concentration pattern appears in prescriber volume. The top 10% of antibiotic prescribers by volume were responsible for 12.5 million antibiotic prescriptions, or 36% of all such prescriptions in the 2021 Medicare Part D analysis (CDC antibiotic use report). That is a strong signal for targeted feedback, audit, and education. If a small subgroup accounts for more than a third of prescriptions, stewardship efforts can be more precise than broad and generic.
Hospital and long-term care stewardship benchmarks
Hospital stewardship data in the dataset are more about program maturity than about infusion volume. In 2024, 97% of hospitals met all 7 CDC hospital antibiotic stewardship core elements (CDC antibiotic use report). That is a strong baseline. But the more demanding stewardship priorities show more variation: in 2024, only 16% of hospitals met all six CDC hospital stewardship priorities, and 36% met five of the six priorities (CDC antibiotic use report).
Those numbers suggest an important distinction. A hospital can meet the core elements while still falling short on the more advanced or operationally intensive priorities. That is useful when reading antibiotic infusion statistics, because infusion therapy often depends on execution details that live below the level of policy adoption.
Hospital benchmark table
| Measure | 2024 value | Source |
|---|---|---|
| Hospitals meeting all 7 antibiotic stewardship core elements | 97% | CDC antibiotic use report |
| Hospitals meeting all 6 stewardship priorities | 16% | CDC antibiotic use report |
| Hospitals meeting 5 of 6 stewardship priorities | 36% | CDC antibiotic use report |
| Long-term care facilities meeting all 7 core elements | 82% | CDC antibiotic use report |
Long-term care facilities show a different pattern. In 2024, 82% of long-term care facilities met all 7 antibiotic stewardship core elements (CDC antibiotic use report). That is lower than the hospital figure, but still substantial. It also fits the long-term care segment’s vulnerability to respiratory infections, transfers, and complex medication use.
The CDC report adds a COVID-related perspective that ties stewardship to changing treatment practice. Prior to FDA authorization of oral antivirals in December 2021, 23% of COVID-19 diagnoses in the long-term care study were associated with an antibiotic order (CDC antibiotic use report). After those authorizations, the antibiotic-order share tied to COVID-19 diagnoses fell to 17% (CDC antibiotic use report). At the same time, 18% of COVID-19 diagnoses in the long-term care study were associated with an antiviral prescription after those authorizations (CDC antibiotic use report).
That shift is important because it shows how medication selection can change when the treatment environment changes. The antibiotic-order decline does not by itself explain the whole picture, but it does show that prescribing behavior is responsive to available alternatives.
Intravenous antibiotic use in hemodialysis
If one setting in the dataset makes the phrase antibiotic infusion statistics feel concrete, it is hemodialysis. Among outpatient hemodialysis patients, almost one in three receives an intravenous antibiotic each year (CDC antibiotic use report). That is a high-exposure population. It means infusion is not a niche delivery route in this setting; it is routine enough to be part of recurring care planning.
The CDC report adds a second critical point: nearly half of the intravenous antibiotics given to hemodialysis patients may not be necessary (CDC antibiotic use report). That is the kind of statistic that changes how infusion data should be interpreted. A high infusion rate can reflect clinical need, but it can also reflect overuse or conservative prescribing practices.
There is also a trend line. From January 2012 to March 2020, adjusted rates of new intravenous antibiotics in outpatient hemodialysis centers decreased by nearly 7% per year (CDC antibiotic use report). During the COVID-19 pandemic period through December 2021, those hemodialysis intravenous antibiotic start rates decreased by about 9% annually (CDC antibiotic use report). That suggests the long-run direction was downward, and the pandemic period accelerated the decline.
Hemodialysis comparison points
- About 1 in 3 outpatient hemodialysis patients receives an intravenous antibiotic each year (CDC antibiotic use report).
- Nearly half of those intravenous antibiotics may not be necessary (CDC antibiotic use report).
- New intravenous antibiotic starts decreased by nearly 7% per year from January 2012 to March 2020 (CDC antibiotic use report).
- During the pandemic period through December 2021, the decline was about 9% annually (CDC antibiotic use report).
- Patients with central venous catheters had much higher intravenous antibiotic rates than patients with a graft or fistula (CDC antibiotic use report).
The access-method difference matters as much as the total rate. Patients with central venous catheters had much higher intravenous antibiotic rates than patients with a graft or fistula (CDC antibiotic use report). That pattern points to a clinical reality: device type is part of infection risk, and infection risk is part of infusion volume. For readers comparing antibiotic infusion statistics across dialysis populations, the access route is one of the most important context variables in the dataset.
What FDA labels say about infusion timing and adverse reactions
The FDA-label portion of the dataset is where antibiotic infusion statistics turn into administration guidance. These label statements are not general trends; they are drug-specific instructions or safety findings. That makes them useful for anyone comparing infusion protocols, adverse reaction profiles, or duration of administration.
Drug-label infusion snapshot
| Drug or label | Infusion or administration detail | Safety or trial note | Source |
|---|---|---|---|
| DALVANCE | Administered by intravenous infusion over 30 minutes | Intended to minimize infusion-related reactions | Dalvance FDA label |
| Oritavancin | Single 1,200 mg IV dose studied by 1-hour infusion and 3-hour infusion | 50 patients in the 1-hour group; 52 in the 3-hour group | Oritavancin FDA label |
| Daptomycin | Adults can receive a 2-minute injection or 30-minute infusion | Pediatric patients 7 to 17 years should receive 30-minute infusion; ages 1 to 6 years should receive 60-minute infusion | Daptomycin FDA label |
| Vancomycin | Should be administered in a diluted solution over 60 minutes or greater | Rapid administration can cause hypotension, shock, cardiac arrest, wheezing, dyspnea, pruritus, and erythema | Vancomycin FDA label |
DALVANCE has the clearest infusion-duration statement in the dataset. It is administered by intravenous infusion over 30 minutes to minimize infusion-related reactions (Dalvance FDA label). The clinical trial data in the same label add context: serious adverse reactions occurred in 109 of 1,778 patients, or 6.1%, while the comparator rate was 80 of 1,224, or 6.5% (Dalvance FDA label). DALVANCE was discontinued because of an adverse reaction in 53 of 1,778 patients, or 3.0%, versus 35 of 1,224, or 2.8% for the comparator (Dalvance FDA label).
The most common DALVANCE adverse reaction was nausea at 5.5% (Dalvance FDA label). Other reactions included headache at 4.7%, diarrhea at 4.4%, vomiting at 2.8%, rash at 2.7%, and pruritus at 2.1% (Dalvance FDA label). The median duration of adverse reactions was 4.0 days in both treatment groups (Dalvance FDA label). Those numbers matter because they help separate administration convenience from tolerability.
Oritavancin shows a different dosing and infusion picture. In the pooled ABSSSI trials, 540 of 976 oritavancin patients, or 55.3%, reported at least one adverse reaction, compared with 559 of 983 vancomycin comparator patients, or 56.9% (Oritavancin FDA label). That is a close comparison on overall adverse-reaction reporting. More specific events in the oritavancin program included nausea at 9.9%, headache at 7.1%, vomiting at 4.6%, diarrhea at 3.7%, dizziness at 2.7%, infusion site phlebitis at 2.5%, infusion site reaction at 1.9%, alanine aminotransferase increased at 2.8%, aspartate aminotransferase increased at 1.8%, tachycardia at 2.5%, and abscesses of the limb or subcutaneous tissue at 3.8% (Oritavancin FDA label).
The KIMYRSA study in the same label is useful because it compares infusion durations directly. 50 patients received a single 1,200 mg intravenous dose by 1-hour infusion, and 52 patients received a single 1,200 mg intravenous dose by 3-hour infusion (Oritavancin FDA label). That gives readers a direct example of how infusion duration can be studied as part of the label, not just as a protocol detail.
Daptomycin is useful because its administration route changes by age group. Adults can receive daptomycin by a 2-minute injection or a 30-minute intravenous infusion (Daptomycin FDA label). For pediatric patients, the route is more specific: ages 7 to 17 years should receive daptomycin by 30-minute infusion, while ages 1 to 6 years should receive a 60-minute infusion (Daptomycin FDA label). Adults with cSSSI receive 6 mg/kg once every 24 hours for 2 to 6 weeks, and the label notes limited safety data for therapy lasting more than 28 days (Daptomycin FDA label).
The pediatric bacteremia trial provides more context. Daptomycin was discontinued in 3 of 55 pediatric patients, or 5.5%, compared with 2 of 26, or 7.7%, in the comparator arm (Daptomycin FDA label). Vomiting occurred in 6 of 55 daptomycin patients, or 10.9%, and blood CPK increased in 4 of 55, or 7.3% (Daptomycin FDA label). Mean duration of IV treatment was 12 days (Daptomycin FDA label). The trial included 69% male and 31% female patients, and no patients younger than 2 years were enrolled (Daptomycin FDA label).
Vancomycin is the clearest warning example in the dataset. It should be administered in a diluted solution over 60 minutes or greater to reduce infusion reactions (Vancomycin FDA label). In adults, concentrations of no more than 5 mg/mL are recommended, while selected fluid-restricted patients may use concentrations up to 10 mg/mL (Vancomycin FDA label). Adult dosing in the label is 2 g per day, divided as either 0.5 g every 6 hours or 1 g every 12 hours (Vancomycin FDA label). Pediatric patients 1 month and older are labeled for 10 mg/kg per dose every 6 hours (Vancomycin FDA label).
The safety warning is explicit. Rapid vancomycin administration can cause hypotension, including shock and cardiac arrest, and can also cause wheezing, dyspnea, pruritus, and erythema of the face, neck, and upper torso known as vancomycin infusion reaction (Vancomycin FDA label). For any article built around antibiotic infusion statistics, this is the label language that makes infusion timing more than a scheduling detail. It is a safety parameter.
How to read these statistics together
The strongest pattern in the dataset is that antibiotic infusion is not one single subject. It is a mix of outpatient prescribing, stewardship compliance, dialysis practice, and drug-label administration rules.
A few practical patterns stand out:
- Outpatient antibiotic use remains substantial at 752 per 1,000 patient population in 2024, even with a slight decline from 2023 (CDC antibiotic use report).
- Stewardship maturity is high on basic elements but lower on more demanding priorities, especially in hospitals (CDC antibiotic use report).
- Hemodialysis is a major infusion-heavy setting, with nearly one in three patients receiving an IV antibiotic each year and nearly half of those IV antibiotics possibly unnecessary (CDC antibiotic use report).
- Drug labels vary sharply in infusion time, from 2-minute injection or 30-minute infusion options for daptomycin adults to 60 minutes or greater for vancomycin, and 30 minutes for DALVANCE (FDA labels).
- Comparative trial data in the labels show that infusion administration is closely tied to adverse reaction profiles, not just convenience (Dalvance FDA label; Oritavancin FDA label; Daptomycin FDA label; Vancomycin FDA label).
If you are using antibiotic infusion statistics for content strategy, clinical operations, or education, the most defensible angle is to keep the setting visible. A dialysis statistic means something different from an outpatient prescribing statistic. A hospital stewardship benchmark means something different from a label-based infusion time. The dataset is strongest when those distinctions stay intact.